Indian-origin doctor studied the safety and benefit of the drug for COVID-19 patients
|
|
|
|
|
| | A real-world study spanning six continents and nearly 100,000 patients — the largest of its kind — finds no evidence of a reduction in death rate among COVID-19 patients who were treated with hydroxychloroquine or chloroquine analogues. However, it did observe that patients treated with hydroxychloroquine or chloroquine were far more likely to experience abnormal and rapid heart rhythms, known as ventricular arrhythmias, than those who had not received the drugs.
The anti-malarial medicine has been touted as a “game-changer” by the US President Donald Trump. The US Food and Drug Administration (FDA) while warning of the use of hydroxychloroquine in ambulatory patients, has also provided an emergency use authorisation (EUA) for the off-label use of these drugs on hospitalised patients with COVID-19.
Last Friday, a revised Indian government advisory recommended use of hydroxychloroquine as a preventive medication for asymptomatic healthcare workers working in non-COVID-19 hospitals, frontline staff on surveillance duty in containment zones and paramilitary/police personnel involved in coronavirus infection related activities. |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| New to this email? You can sign up here.
You can also follow HuffPost India on Flipboard.
©2019 HuffPost lndia | Level 3B, DLF Centre, Sansad Marg, Connaught Place, New Delhi - 110001, India You are recieving this email becuase you signed up for updates from HuffPost India.
Feedback | Privacy Policy | Unsubscribe |
|
|
|
|
|
 |
0 comments:
Post a Comment